文献速递口腔修复与种植

顺铂化疗损害钛种植体周围骨修复:大鼠体内研究

Cisplatin chemotherapy impairs the peri-implant bone repair around titanium implants: An in vivo study in rats.
PubMed 文献 · J Clin Periodontol · 2017-12-05

该动物研究将84只雄性大鼠分为顺铂组和生理盐水组,在术后第15、17天腹腔给药,评估钛种植体周围骨修复。结果显示顺铂组骨-种植体接触率和骨面积均降低,RUNX-2和骨钙素阳性细胞减少,TRAP阳性细胞增多,并持续存在炎症反应,表明顺铂损害种植体骨整合。

要点

  • 顺铂化疗可降低钛种植体周围骨-种植体接触率和骨面积。
  • 顺铂组RUNX-2和骨钙素阳性细胞减少,TRAP阳性细胞增多。
  • 顺铂组所有实验期均见持续加重的炎症反应。

核心结论

  • 顺铂 negatively 影响种植体周围骨修复,危及钛种植体的骨整合。

研究设计与样本

  • 所有动物第0天在右胫骨植入钛种植体,术后第15、17天分别腹腔注射顺铂(5和2.5 mg/kg)或生理盐水。
  • 术后22、30、60天处死动物,24个未脱钙标本用于骨-种植体接触率(BIC)组织形态计量分析,60个标本用于骨面积(BA)测量、组织学和免疫组化分析。

主要发现

  • 顺铂组BIC在22、30、60天分别为11.87±0.97 mm、19.19±0.8 mm、17.69±1.05 mm,均低于生理盐水组(p≤.05)。
  • 顺铂组BA在22、30、60天分别为3.68±1.29 mm2、3.05±0.88 mm2、3.23±0.67 mm2,均低于生理盐水组(p≤.05)。
  • 顺铂组RUNX-2阳性细胞数在22、30、60天分别为102.8±27.35 cells/mm2、100.04±8.61 cells/mm2、118.82±21.38 cells/mm2,均低于生理盐水组(p≤.05)。
  • 顺铂组骨钙素阳性细胞数在22、30、60天分别为120±24.5 cells/mm2、102±27.73 cells/mm2、100±14.23 cells/mm2,均低于生理盐水组(p≤.05)。
  • 顺铂组TRAP阳性细胞数在22、30、60天分别为86.8±6.37 cells/mm2、71.5±4.72 cells/mm2、92.8±9.52 cells/mm2,均高于生理盐水组(p≤.05),且所有实验期均见持续加重的炎症反应。

临床怎么用

  • 对于接受顺铂化疗的患者,种植体周围骨愈合可能受损,需谨慎评估种植时机与预后。

局限性

  • 本研究为动物实验,结果外推至人类需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIM: The purpose of this study in animals was to evaluate the peri-implant bone repair against systemic administration of the antineoplastic agent. MATERIAL AND METHODS: We used 84 male rats (Rattus norvegicus, albinus, Wistar), divided into two groups: cisplatin (CIS) and saline solution (SS). The titanium implants were inserted into the right tibia at day 0 in all animals from both groups. Group SS received SS intraperitoneally at 15 and 17 days postoperatively. Group CIS received 5 and 2.5 mg/kg of CIS intraperitoneally at 15 and 17 days postoperatively, respectively. Euthanasia was performed at 22, 30 and 60 days postoperatively. Twenty-four undecalcified specimens were prepared for histometric analysis of bone/implant contact (BIC). Sixty specimens were selected to bone area (BA) measurement, histological analysis and immunohistochemical analysis of RUNX-2, osteocalcin (OCN) and tartrate-resistant acid phosphatase (TRAP). BIC and BA were considered to be the primary outcome parameters. RESULTS: Group CIS showed lower BIC (11.87 ± 0.97 mm; 19.19 ± 0.8 mm; 17.69 ± 1.05 mm; p ≤ .05) and BA (3.68 ± 1.29 mm2 ; 3.05 ± 0.88 mm2 ; 3.23 ± 0.67 mm2 ; p ≤ .05), as well as decreased number of RUNX-2 (102.8 ± 27.35 cells/mm2 ; 100.04 ± 8.61 cells/mm2 ; 118.82 ± 21.38 cells/mm2 ; p ≤ .05)- and OCN-positive cells (120 ± 24.5 cells/mm2 ; 102 ± 27.73 cells/mm2 ; 100 ± 14.23 cells/mm2 ; p ≤ .05) at 22, 30 and 60 days, respectively. The animals in group CIS also showed increased number of TRAP-positive cells (86.8 ± 6.37 cells/mm2 ; 71.5 ± 4.72 cells/mm2 ; 92.8 ± 9.52 cells/mm2 ; p ≤ .05) and a persistent and exacerbated inflammatory response in all experimental periods. CONCLUSION: Within the limits of this study, it was concluded that the chemotherapeutic CIS negatively affects the bone repair at peri-implant areas, jeopardizing the osseointegration of titanium implants.

来源:J Clin Periodontol,查看原文。版权归原作者所有。

引用

  1. Matheus HR, Ervolino E, Faleiros PL, et al. Cisplatin chemotherapy impairs the peri-implant bone repair around titanium implants: An in vivo study in rats. J Clin Periodontol. 2017. PMID: 28965362. doi:10.1111/jcpe.12824

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。